Represents the amount to be paid by the entity on achievement of various milestones.

No definition available.

Name:	opht_AmountToBePaidOnAchievementOfMilestone
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Asset Acquisition, Clinical And Marketing Approval Milestones

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionClinicalAndMarketingApprovalMilestones
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Contingently Issuable Shares As A Percentage Of Shares Outstanding

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsContingentlyIssuableSharesAsAPercentageOfSharesOutstanding
Namespace Prefix:	opht_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Shares Issuable, High

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesSharesIssuableHigh
Namespace Prefix:	opht_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Asset Acquisition, Contingent Consideration Arrangements, Range Of Outcomes, Value, High

+ References

No definition available.

+ Details

Name:	opht_AssetAcquisitionContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix:	opht_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- References

No definition available.

+ Details

Name:	opht_CommitmentsAndContingenciesLineItems
Namespace Prefix:	opht_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Commitments and Contingencies (Details) - USD ($) shares in Millions, $ in Millions		1 Months Ended
	Oct. 30, 2018	Oct. 31, 2018	Dec. 31, 2018
Commitments and contingencies
Loss contingency estimate, plaintiff's counsel fees			$ 0.3
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified clinical and regulatory milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone			57.5
License Agreements \| Archemix \| C5 Licensed Product \| First indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone			30.5
License Agreements \| Archemix \| C5 Licensed Product \| Second and third indication \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone			24.5
License Agreements \| Archemix \| C5 Licensed Product \| Sustained delivery applications \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone			2.5
License Agreements \| Archemix \| C5 Licensed Product \| Achievement of specified commercial milestones \| Maximum
Commitments and contingencies
Amount to be paid on achievement of milestone			22.5
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Clinical, Marketing Approval and Reimbursement Approval Milestones Related to a Licensed Product
Commitments and contingencies
Amount to be paid on achievement of milestone			23.5
RHO-adRP License Agreement \| University of Florida Research Foundation (UFRF) \| Specified Commercial Sales Milestones Related to a Licensed Product
Commitments and contingencies
Amount to be paid on achievement of milestone			$ 70.0
Inception 4
Commitments and contingencies
Contingent consideration	$ 105.0	$ 105.0
Contingently issuable shares, asset acquisition (in shares)	7.2	7.2
Contingently issuable shares, asset acquisition, as a percentage of total shares outstanding	19.90%	19.90%
Inception 4 \| GA
Commitments and contingencies
Clinical and marketing approval milestones	$ 45.0
Inception 4 \| Wet AMD
Commitments and contingencies
Clinical and marketing approval milestones	$ 60.0